Luxica Pharma

Luxica Pharma is a clinical-stage biotechnology company focused on developing long-acting, sustained-release therapeutics for the treatment of chronic retinal diseases. The company's primary mission is to reduce the frequent injection burden associated with current standard-of-care treatments for conditions such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Luxica utilizes a proprietary bioerodible delivery platform designed to provide stable, multi-month therapeutic levels of medication within the eye. Its lead candidate, LX-101, is an intravitreal insert that releases a potent tyrosine kinase inhibitor. Founded by industry veterans with extensive experience in ophthalmic drug development, the company aims to improve patient outcomes through more consistent and convenient dosing regimens.